Cita APA

Klochikhin, A., Isaev, P., Badiu, C., Robinson, B., Capdevila Castillon, J., & Leboulleux, S. (2022). A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.

Citación estilo Chicago

Klochikhin, Arkadiy, Pavel Isaev, Corin Badiu, Bruce Robinson, Jaume Capdevila Castillon, y Sophie Leboulleux. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet At 60 mg Per Day Compared With the Cabozantinib Capsule At 140 mg Per Day in Patients With Progressive, Metastatic Medullary Thyroid Cancer. 2022.

Cita MLA

Klochikhin, Arkadiy, et al. A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet At 60 mg Per Day Compared With the Cabozantinib Capsule At 140 mg Per Day in Patients With Progressive, Metastatic Medullary Thyroid Cancer. 2022.